Calypte und die Zeit nach AIDS2004 in Bangkok

MMD  Ask Ask Size
GNET  0.430 150  
TDCM ↑  0.430 50
 

 

 

...und schreibe wenigstens "Psychiater". das ist ja grausam mit deiner rechtschreibschwäche...

was soll kade nur über soviel "Diletantismus" sagen. das "niwo" geht sonst zu stark in den keller

achso:

Last 10 trades


Time  Price  Volume  Exchange  Info


12:15:08    0.430 3900 OTCBB  
12:15:08    0.430 1000 OTCBB  
12:15:08    0.430 100 OTCBB  
12:15:08    0.430 5000 OTCBB  
12:14:38    0.430 2000 OTCBB  
12:12:17    0.430 10000 OTCBB  
12:11:49    0.420 5000 OTCBB  
12:09:10    0.430 10000 OTCBB at Ask
12:08:24    0.430 2600 OTCBB at Ask
12:07:51    0.430 2400 OTCBB at Ask
 

Rechtschreibreform in aller Munde und ob Pschiater oder Pschychiater oderPsychiater
ist doch egal alles stimmt oder wie sagt mann
was genaues weis mann nicht  

schon am anfang gesagt.da hat dieser wieder einen zusammenbruch bekommen und geweint.versteh also das du in dieser sprache mit ihm reden mußt.gute therapie.übrigens ist mein ü und p auch defekt.naja, das kann jemand der diesem thread so kurz angehört nicht erkennen. ;O)  

schließen.
Zu Risiken und nebenwirkungen fragen sie bis auf weiteres das Ariva-Team
werde jetzt einen gepflegten Skat dreschen und ein paar Biere kippen.
Wünsche euch ein wohlverdientes WE.
Mfg Lucky allias Joelupschichiarer
 

man als externer nicht erkennen, da ich nicht zum EXPERTENTEAM gehöre...  

 

Posted by: sower
In reply to: flavius22 who wrote msg# 183 Date:8/13/2004 3:15:35 PM
Post #of 185

flavius...

I think you're a little low on your calculations for pps of $3.75.

When you used gross sales for Orasure and net profit for Calypte, you compared apples to oranges.

If you use the NASD financials, it shows Orasure gross earnings for the first half of 2004 at 25M. Multiply x 2, and it comes to 50M for the whole year. Your figure was 70M.

Looking at Calypte....

Using your estimate of 50M kits (50M x 4 countries = 200M) at a price of at least $2.00 per kit, that's 400M gross sales. That's 8 x bigger than Orasure.

Orasure is trading at $5.34 / share on 37.7M outstanding shares. Right now the stock is trading at about 4x earnings.

If Calypte's gross sales were at 400M and the os is 168M, using the same valuation of 4x earnings, Calypte would be trading at $8.30 / share.

Back in June, Osure was trading at over $10.00 / share, the valuation at that time was 7.4 x earnings.

Using the same valuation of 7.4 for Calypte, the price would be $17.62 / share.

My own opinion... all of us are going to be glad we invested in Calypte

sower

 

Aktien? wieder mal eine falsche Aussage von dir, leider siehe hier
aus Investors Hub.


Insider Stockholders

Shares as of July 22, 2004
...............................................Shares Owned.....................$2.00..................................­...$5.00......................................$8.00
--------------------------------------------------
Anthony J. Cataldo...................5,022,341.................$10,044,682.0­0....................$25,111,705.00....................$40,178,72­8.00
Executive Chairman
of the BOD

Richard George, Ph.D...............2,551,273.................$5,102,546.00.......­.............$12,756,635.00....................$20,410,184.00
President & Chief
Exec. Officer

Richard Brounstein...................1,507,371..................$3,014,74­2.00......................$7,536,855.00....................$12,05­8,968.00
Executive VP

Paul Freiman...............................309,901....................­....$619,802.00.......................$1,549,505.00..............­.......$2,479,208.00
President and Chief
Executive Officer

Julius R. Krevans, M.D..............308,468.........................$616,936.00.....­...................$1,542,340.00....................$2,467,744.00­
Chancellor Emeritus,
Director of Intl. Med. Care

John J. DiPietro..........................307,977........................­.$615,954.00.......................$1,539,885.00.................­....$2,463,816.00
Chief Financial Officer
VP of Finance & Admin.

I don't know what they purchased these shares for, but if they want to receive the dollars listed here, they will not want to dilute anymore shares.
Diluting is a method of paying for expenses. If they begin selling product soon, the company can begin using income to sustain the operations of the company.

sower

 

sind.
The Show must go on !  

...falsche aussage"? meine sonstigen aussagen waren und sind richtig?

wo hast du diese passage her? dann gib mir bitte mal die genaue stelle an!

im letzten filing vom 09.08 findest du jedenfalls nichts darüber! hast du womöglich am ende ein altes filing zur hand genommen? (lach)

dafür habe ich nochmal das für dich bzw. euch:

The registrant had 168,044,755 shares of common stock outstanding as of August 6, 2004.


From inception through August 6, 2004, we have issued approximately 168.0 million shares of our common stock and raised approximately $140 million. At a Special Meeting of Stockholders on February 14, 2003, our stockholders approved an increase in the number of authorized shares of the Company's common stock from 200 million to 800 million. Although we have no plans to do so, at August 6, 2004, we have the ability, without further stockholder approval, to issue in excess of 500 million shares of our common stock for financing or for other purposes. The perceived risk of dilution from this amount of authorized but unissued stock may cause our existing stockholders and other holders to sell their shares of stock, which would contribute to a decrease in our stock price. In this regard, significant downward pressure on the trading price of our stock may also cause investors to engage in short sales, which would further contribute to significant downward pressure on the trading price of our stock.
 

Additionally,  following  the 1:30 reverse split of our common stock that became
effective in May 2003, we currently have over 500 million shares of common stock
that could be issued without further stockholder approval. Although there are no
current  plans to issue such a large number of shares,  the  dilution  resulting
from such issuance could also adversely  affect the rights of our current common
stockholders.  

A Market for Our Products May Not Develop.

Our future  success  will depend,  in part,  on the market  acceptance,  and the
timing of such acceptance, of new products such as our developmental stage rapid
HIV tests and  other new  products  or  technologies  that may be  developed  or
acquired.  To achieve  market  acceptance,  we must make  substantial  marketing
efforts and spend significant funds to inform potential customers and the public
of the perceived benefits of these products.  We currently have limited evidence
on which to evaluate the market reaction to products that may be developed,  and
there can be no assurance  that any products will obtain market  acceptance  and
fill the market need that is perceived to exist  

We Have Limited Experience Selling and Marketing Our HIV-1 Urine ELISA Tests and
No Experience Marketing a Rapid Test.

Our  urine-based  ELISA products  incorporate a unique method of determining the
presence of HIV antibodies and we have limited experience  marketing and selling
them either  domestically  or  internationally.  Further,  we have no experience
marketing  and  selling  blood or oral fluid  products.  Our  company's  success
depends upon alliances with  third-party  international  distributors  and joint
venture partners and upon our ability to penetrate  expanded markets.  There can
be no assurance that:

    o    our  international  distributors and joint ventures will  successfully
         market our products;

    o    our domestic selling efforts will be effective;

    o    we  will  obtain  any  expanded  degree  of  market  acceptance  among
         physicians,  patients or health care payors;  or others in the medical
         or public health  community,  including  governments and  humanitarian
         funding  sources  critical  in may  international  markets,  which are
         essential for acceptance of our products; or

    o    if our relationships with distributors  terminate,  we will be able to
         establish relationships with other distributors on satisfactory terms,
         if at all.
 

7.0 TERMINATION. 7.1 ABBOTT shall have the right to terminate this Agreement if CALYPTE has materially defaulted in the performance of any of its royalty payment obligations herein contained, and such default has not been cured within thirty (30) days after written notice from ABBOTT affirming its intention to terminate.  

werden erwartet von mir
Lucky  

 

Form 8-K for CALYPTE BIOMEDICAL CORP


--------------------------------------------------

16-Aug-2004

Other Events, Financial Statements and Exhibits



ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
The Registrant (the "Company") announced on August 16, 2004 that its common stock, $0.03 par value (the "Common Stock") has been approved for listing on the American Stock Exchange ("Amex"). The Company currently has 168,044,755 shares of Common Stock issued and outstanding. It has also established reserves for an aggregate of 73,830,636 shares of Common Stock potentially issuable pursuant to its benefit plans, warrant grants and certain financing agreements, including 30,000,000 million shares potentially issuable under the 2004 Incentive Plan that was recently approved by its stockholders and approximately 11,500,000 shares potentially issuable upon the exercise of warrants granted in conjunction with its recent private placements. Amex has approved for listing a total of 241,875,931 shares of the Company's outstanding or potentially issuable Common Stock. The Company's Common Stock is expected to commence trading on the Amex on August 18, 2004 under the symbol "HIV".

The Company, as part of its application for listing on the Amex, has agreed that it will be subject to AMEX rules that will require it obtain stockholder approval of any future private placement transaction that results in the issuance of 20% or more of its then-outstanding Common Stock or any transaction that triggers existing anti-dilution provisions which require the Company to issue additional shares of its common stock. The current Amex listing approval does not include any such additional shares.

Annexed hereto as Exhibit 99.1 is a copy of the press release issued by the Company.





ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS  

e viva el calypso  

ich kann es zwar nicht glauben und es kommt mir auch spanisch vor: wieder nur ein PR-GAG und bauernfängerei oder wirklich eine wiedergeburt?


wenn es aber wirklich keine ente ist und es ohne wenn und aber ein amex-lisitg in 2 tagen gibt, dann ist das sicherlich sehr positiv zu sehen.

es wird einigen die chance geben ihre verluste zu minimieren, sofern sie aussteigen.

allerdings bleibe ich bei meiner prognose: ohne großaufträge ist das ding bei der cash-burn-rate platt!!!!

dann sind die investierten nach einem anstieg schnell wieder da, wo sie jetzt herkommen. das amex-listing alleine spielt keine umsätze ein.

was mich wundert, dass das ganze innerhalb von 2 tagen vonstatten geht und nicht zum monatsanfang. das macht mich etwas stutzig.

wie konnte man es schaffen, bei den umsätzen im verhältnis zur mk ein amexlisting zu bekommen?

vor allem das kürzel: "HIV" lässt mich doch sehr grinsen. hört sich eher nach einer ente an, scheint aber zu stimmen...so scheint es.


wie dem auch sein: ihr habt die sonne ohne wenn und aber erst einmal auf eurer seite. ihr werdet sicherlich eine gute chance zu einem guten kurs bekommen, eure verluste zu minimieren....oder sollte das listing keinen einfluss auf den kurs haben?

schwer zu sagen, aber eigentlich ist es kurzfrisitg sehr sehr positiv zu sehen.  

Calypte Biomedical Corp. (ticker: CYPT.OB, exchange: Other OTC) News Release - 16-Aug-2004


--------------------------------------------------
Calypte Biomedical Approved for Listing on AMEX: HIV

              Trading Expected to Begin Wednesday August 18th
PLEASANTON, Calif., Aug. 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT) today announced that its common stock has been approved for listing on the American Stock Exchange ("Amex"). Calypte's common stock is expected to commence trading on the Amex under the symbol "HIV" on Wednesday, August 18, 2004.

"Calypte's listing on the Amex is another significant objective in the progress of our company," said Anthony Cataldo, Chairman of Calypte. "The listing provides greater visibility for Calypte and a listing with Amex eliminates certain restrictions inherent in being traded on the OTC Bulletin Board. Often these restrictions limit certain brokers and institutions in their ability to trade bulletin board stocks."

Calypte, under the symbol "CYPT" is expected to stop trading on the OTC Bulletin Board at the close of business, August 17, 2004 and is expected to commence trading on the Amex on Wednesday, August 18, 2004 under the symbol "HIV".

 

 

stand hier noch nicht !

Grüße